David M. Goldstein

Executive

Insider activity · 24 months0 buys1 saleCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 1 saleSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (0 ops.)

—

▼ Sales (9 ops.)

€845k

Latest filing published 05 Aug 2026 for ALUMIS INC., €59k.

Filing timeline

BuySale

David M. Goldstein

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

No signal scores available.

David M. Goldstein: trading record in brief

David M. Goldstein has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Principia Biopharma Inc. and Alumis Inc. We count 18 filings; the first trade dates from 7 May 2020 and the latest from 3 August 2026.

The open-market record consists of 9 sales worth €845k, with no purchase. Outside the open market, there are 3 share grants and 3 option exercises. Since January 2026: no purchases and 1 sale on the market.

Most recently, on 5 August 2026, the filings show an open-market sale worth €59k in Alumis Inc. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.